Regeneron Pharmaceuticals Inc annual free cash flow for fiscal TTM was $4.2 billion, an increase of 1.8% from $4.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $4.2B | $4.1B | $3.7B | $3.7B | $4.4B | $6.5B | $2.0B | $2.0B | $1.8B | $1.0B | $974M | $653M | $419M | $432M | ($124M) | ($199M) | ($3M) | ($170M) | ($124M) | $9M | $20M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $848M | $922M | $1.4B | $968M | $774M | $996M | $1.1B | $143M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More REGN metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All REGN financial statements → Interactive REGN charts →
About TickerBase · Data methodology & sources